Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...

Novartis says it intends to launch a variety of US patient access programmes to support ... insurance coverage and providing financial assistance for the uninsured or underinsured.

US FDA grants accelerated approval to Novartis’ Scemblix for adult patients with newly diagnosed Ph+ CML-CP: East Hanover Thursday, October 31, 2024, 12:00 Hrs [IST] Novartis an ...

Scemblix was granted accelerated approval by the FDA for the treatment of certain patients newly diagnosed with chronic ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs. The company said it anticipates full-year operating ...

Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs.

A new survey shows that three Big Pharmas have stolen the hearts of patient groups representing nearly 1 million people with cardiovascular conditions. | A new survey shows that three Big Pharmas have ...

Find out why Boehringer, Amgen and Novartis have been awarded the highest reputation scores by several cardiovascular patient ...

Novartis (NVS) has released an update. Novartis’ Scemblix has received FDA approval as a first-line treatment for newly diagnosed chronic ...

Gagan Singh Chandhiok, a patient from Karnataka alleged, “We have been dealing with this shortage for years.” Novartis ...

Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...